The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. This conference covers commercialization hurdles facing the cell and gene therapy sector as well as a wide range of topics from clinical trial design, alternative payment models, scale-up and supply chain platforms for advanced therapies.
Featured agenda item
Alternative IPO Strategies for Cell and Gene Therapy Companies
On Demand – Monday, October 12, 2020
Cooley partner Yvan-Claude Pierre is a featured
speaker.
This session will center on special purpose acquisition companies (SPACs), a space heating up within the biotech world. As of August 2020, 10 biotech-focused SPACs have been successful at raising capital with many others coming down the pike. The purpose of the panel is to understand why all these biotech-focused firms are getting involved in the space, what cell and gene therapy companies need to know about this alternative to a traditional IPO if approached, and what seasoned executives of public companies should know about potentially sponsoring their own biotech focused SPAC.